

Natraj Proteins Limited

**SOLVENT EXTRACTION PLANT & REFINERY
Nagpur Kalan, Ordinance Factory Road, ITARSI**

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email : natrajproteinltd@rediffmail.com

CIN : L00153 MP 1990 PLC 006090



Ref. :

Date :

NPL/SE/2020

9th November, 2020

Online filing at www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
MUMBAI - 400001

BSE CODE: 530119

Sub: Submission of the Standalone Un-Audited Quarterly Financial Results alongwith the Statement of Assets & Liabilities and Cash Flow and Limited Review Report for the Half year/Quarter ended 30thSeptember, 2020 u/r 33 of the SEBI (LODR) Regulations, 2015.

Dear Sir,

This is in continuation of our letter no. NPL/SE/2020 dated 29th October, 2020 regarding intimation of Board meeting for consideration and approval of the Quarterly Standalone Un-Audited Financial Results alongwith the Statement of Assets & Liabilities and Cash Flow and Limited Review Report thereon, for the Quarter/Half year ended 30th September, 2020.

Pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015 we are pleased to submit the following;

- (a) Standalone Unaudited Financial Results for the Half year/quarter ended 30th September, 2020;
- (b) Statement of Assets & Liabilities for the Half year ended 30th September, 2020;
- (c) Statement of Cash flow for the Half year ended 30th September, 2020 and
- (d) Limited Review Report by the Auditors for the Half year/quarter ended 30th September, 2020,

which was considered and approved by the Board at their 4/2020-21 Meeting held on Monday, the 9th November, 2020.

The Financial Results will also be published in widely circulated English and Hindi (Vernacular) newspaper in the prescribed format for that purpose.

We are also in process of filing the aforesaid financial results in the XBRL format within the stipulated time and same shall be hosted on the Website of the Company.

You are requested to please take on record the above said documents for your reference and record.

Thanking You,

Yours Faithfully,

For, NATRAJ PROTEINS LIMITED

KAILASH CHAND SHARMA
CHAIRMAN AND MANAGING DIRECTOR

DIN: 00012900

Encl.: As above

NATRAJ PROTEINS LIMITED

CIN: L00153MP1990PLC006090

Regd. Off. -Nagpur Kalan, Ordinance Factory Road, Itarsi, (M.P.)-461111

Email: natrajproteinltd@rediffmail.com Website: www.natrajproteins.com

Standalone Unaudited Financial Results for the Quarter/Half Year ended on 30th September, 2020

Part I		(Rs. In Lakhs Except EPS)					
S. No.	Particulars	Quarter			Half Year		Year
		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	6 Months ended	Corresponding 6 Months ended in the previous year	Previous year ended
	(Refer Notes Below)	30/09/2020 (Unaudited)	30/06/2020 (Unaudited)	30/09/2019 (Unaudited)	30/09/2020 (Unaudited)	30/09/2019 (Unaudited)	31/03/2020 (Audited)
I	Income/Revenue from Operations	2918.15	2382.77	2480.39	5,300.92	4780.99	15412.86
II	Other Income	2.00	1.51	2.12	3.51	3.25	4.60
III	Total Income (I+II)	2920.15	2384.28	2482.51	5,304.43	4784.24	15417.46
IV	Expenses						
a	Cost of Materials consumed	1913.36	2522.85	1899.20	4,436.21	3793.41	12150.19
b	Purchase of Stock-in-Trade	246.27	184.16	207.02	430.43	1268.35	1734.22
c	Changes in inventories of finished goods stock-in-trade and work-in-progress	810.07	(343.51)	149.64	466.56	(738.88)	480.87
d	Employee benefits expense	28.52	29.08	33.12	57.60	63.21	132.23
e	Finance Costs	26.49	67.88	95.85	94.37	201.69	361.09
f	Depreciation and amortization expense	4.77	15.35	15.41	20.12	32.34	63.17
g	Other expenses	70.93	78.63	85.57	149.56	156.67	463.28
	Total Expenses (IV)	3100.41	2554.44	2485.81	5,654.84	4776.79	15385.05
V	Profit/ (Loss) before exceptional items and Tax (I-IV)	(180.26)	(170.16)	(3.30)	(350.41)	7.45	32.41
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(180.26)	(170.16)	(3.30)	(350.41)	7.45	32.41
VIII	Tax expense:						
	(1) Current Tax	-	-	(0.68)	-	1.53	4.62
	(2) Deferred Tax	-	-	-	-	-	(6.10)
IX	Profit / (Loss) for the period from continuing operations (VII-VIII)	(180.26)	(170.16)	(2.62)	(350.41)	5.92	33.89
X	Profit / (Loss) from Discontinuing operations	-	-	-	-	-	-
XI	Tax expenses of Discontinuing	-	-	-	-	-	-



	operations						
XII	Profit / (Loss) from Discontinuing operations (after Tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX+XII)	(180.26)	(170.16)	(2.62)	(350.41)	5.92	33.89
XIV	Other Comprehensive Income:						
	A (i) Items that will not be reclassified to Profit or loss	1.47	2.78	0.26	4.25	0.59	(2.77)
	(ii) Income Tax relating to items that will not be reclassified to Profit or loss	-	-	(0.05)	-	(0.12)	0.43
	B (i) Items that will be re-classified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit/(Loss) and other Comprehensive Income for the period)	(178.79)	(167.38)	(2.41)	(346.16)	6.39	31.55
XVI	Paid up Share Capital of the Company (Face Value Rs. 10/-)	374.70	374.70	374.70	374.70	374.70	374.70
XVII	Reserves excluding revaluation reserves	-	-	-	-	-	3188.97
XVII	Earnings Per Share (for continuing operations)						
	(a) Basic	(4.81)	(4.54)	(0.06)	(9.35)	0.17	0.90
	(b) Diluted	(4.81)	(4.54)	(0.06)	(9.35)	0.17	0.90
XIX	Earnings Per Share (for Discontinued operations)						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XX	Earnings Per Share (for Discontinued and continuing operations)						
	(a) Basic	(4.81)	(4.54)	(0.06)	(9.35)	0.17	0.90
	(b) Diluted	(4.81)	(4.54)	(0.06)	(9.35)	0.17	0.90

Notes:

- These results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time. These



results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 9th November, 2020. The statutory auditors have expressed an unmodified audit opinion on these results.

2. The company operates in two segments i.e. solvent extraction and commodities derivative trading. However, for the current quarter as well as corresponding quarter in previous year there is no requirement of segmental reporting as the sales of commodities/derivatives are less than the threshold limits.
3. Statement of Assets and Liabilities and Statement of Cash flows is attached with these results.
4. Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
5. COVID-19 has affected business operations of the Company with manufacturing, sales, supply chain, cash flows etc. continuing to be impacted. The manufacturing facility of the Company which was shut down from 25th March, 2020 due to country wide lockdown, resumed operations in a phased manner from June, 2020 after obtaining requisite approvals. Plants of the Company operated at below capacity during this quarter. The offices and manufacturing units of the Company started operations in line with the Unlock advisory. The uncertainties associated with the situation continue to evolve and the Company is monitoring them closely. The impact of COVID-19 on the standalone financial results may differ from that estimated as at the date of approval of these results. The Company will keep adjusting as called for from time to time to best cushion the adverse impact from this scenario, if any.
6. The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The effective date from which the changes are applicable is yet to be notified and the rules for quantifying the financial impact are yet to be framed. Based on an initial assessment by the Company and its Indian subsidiaries, the additional impact on Provident Fund contributions by the Company is not expected to be material, whereas the likely additional impact on Gratuity liability/contributions by the Company. The Company will complete their evaluation and will give appropriate impact in the financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
7. Effective from 1st April, 2019, the company has adopted Indian Accounting Standard (IND-AS 116) "Leases" using the "Modified Prospective Approach". The adoption of the said IND AS did not have any impact on the retained earnings as at 1st April, 2020 and there was no material impact on financial results for the quarter/Half Year ended on 30th September, 2020.

Date: 09.11.2020
Place: Itarsi

For, NATRAJ PROTEINS LIMITED


KAILASH CHAND SHARMA
Chairman / Managing Director
DIN: 00012900

Statement of Unaudited Standalone Assets and Liabilities as on 30.09.2020

Particulars	30.09.2020	31.03.2020
	Un-audited	Audited
ASSETS		
(1) Non-Current Assets		
(a) Property, Plant and Equipment	285.85	305.97
(b) Capital Work-in-Progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible assets	-	-
(f) Intangible assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financial Assets		
i. Investments	-	-
ii. Trade receivables	-	-
iii. Loans	78.08	77.13
iv. Others (to be specified)	-	-
(i) Deferred tax assets(net)	-	-
(j) Other non-current assets	267.05	144.93
Total Non-Current Assets	630.98	528.03
(2) Current Assets		
(a) Inventories	2105.85	4218.25
(b) Financial Assets		
i. Investments	-	-
ii. Trade receivables	1553.53	1784.66
iii. Cash and cash equivalents	1214.30	44.57
iv. Bank balances other than (iii) above	-	189.62
v. Loans	87.02	303.99
vi. Other (to be specified)	-	-
(c) Current Tax Assets (Net)	10.30	10.30
(d) Other current assets	-	-
Total Current Assets	4971.00	6551.39
Total Assets	5601.98	7079.42
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	374.70	374.70
(b) Other Equity	2842.81	3188.97
Liabilities		
(1) Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade payables		
- Total outstanding dues of Micro and small enterprises;	-	-
- Total outstanding dues of creditors other than Micro and small enterprises;	-	-
(iii) Other Financial liabilities (other than those specified in item (b), to be specified)	-	-
(b) Provisions	86.80	86.80
(c) Deferred tax liabilities (Net)	-	-
(d) Other non-current liabilities	86.80	86.80
Total Non-Current Liabilities		
(2) Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	1920.94	3085.72
(ii) Trade payables		
- Total outstanding dues of Micro and small enterprises;	234.25	210.40



- Total outstanding dues of creditors other than Micro and small enterprises;	-	-
(iii) Other Financial liabilities (other than those specified in item (c))	143.10	127.18
(b) Other current liabilities	-0.62	5.65
(c) Provisions	-	-
(d) Current Tax Liabilities (Net)	2297.67	3428.95
Total Current Liabilities		
Total Equity and Liabilities	5601.98	7079.42

For, NATRA PROTEINS LIMITED



KAILASH CHAND SHARMA
Chairman & Managing Director
DIN: 00012900.

Date: 09.11.2020
Place: Itarsi

STANDALONE CASH FLOW STATEMENT

FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2020

(Rupees in Lakhs)


Particulars	Half	Year	Year Ended on
	Ended	on	31.03.2020
	30.09.2020		
	Unaudited		Audited
A. CASH FLOW FROM OPERATING ACTIVITIES			
NET PROFIT BEFORE TAXATION AND EXTRAORDINARY ITEM		(346.16)	31.55
ADJUSTMENT FOR:			
Depreciation and amortization expenses		20.12	63.17
Finance costs		94.37	361.09
Indirect tax paid		-	-
Interest Income		3.51	4.61
CSR Expenses		-	6.12
Deferred Tax Asset		-	6.10
Operating Profit before Working Capital Changes		(235.19)	438.99
ADJUSTMENTS FOR :			
Trade Receivables		231.14	199.85
Inventories		2,112.40	(104.25)
Loans, Advances and other current assets		206.66	(183.32)
Current Liabilities		33.50	(162.67)
CASH GENERATED FROM OPERATIONS		-	-
Income tax paid		-	(15.00)
Indirect tax paid		-	-
NET CASH FROM OPERATING ACTIVITIES		2,348.52	173.59
B. CASH FLOW FROM INVESTING ACTIVITIES			
Interest received		3.51	4.61
Purchase of Fixed Asset/Capital WIP		-	(15.55)
Non-Current Assets, Long term loans and advances		(112.77)	22.28
NET CASH USED IN/ FROM INVESTING ACTIVITIES		(109.26)	11.33
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from current borrowings		(1,164.78)	3.50
Proceeds from Long Term Borrowings		-	(5.00)
Interest paid		(94.37)	(361.09)
NET CASH USED IN/ FROM FINANCING ACTIVITIES		(1,259.15)	(362.59)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS		980.11	(177.67)
OPENING CASH AND CASH EQUIVALENTS		234.19	411.86
CLOSING CASH AND CASH EQUIVALENTS		1,214.30	234.19

For, NATRAJ PROTEINS LIMITED

Date: 09.11.2020

Place: Itarsi


KAILASH CHAND SHARMA
 Chairman & Managing Director
 DIN: 00012900



ANUP SHRIVASTAVA & ASSOCIATES CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

To, The Board of Directors of
NATRAJ PROTEINS LIMITED
Itarsi (M.P.)

We have reviewed the accompanying statement of unaudited financial results of Natraj Proteins Limited for the period ended **30th September, 2020**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.


Emphasis Matter

The Company is not required to spend any fresh amount towards CSR for the period under review being the prescribed limits applicable for CSR has not exceeded during the preceding 3 financial years. Further that the company is carrying the unspent amount of Rs.33.48 lakhs for the year 2014-15, 2015-16 and 2016-17. However the Company has expended Rs.6.12 lakhs towards the CSR activities from it. Thus the Company is now required to spend total amount of Rs.27.36 Lakhs.


The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of receivables, unbilled revenues. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the Company, as at the date of approval of these financial statements has used internal and external sources of information including, subsequent payments received from debtors subsequent to the date of the financial statements. The Company based on current estimates expects the carrying amount of these assets will be recovered with extended credit period.

Our conclusion is not modified in respect of these matters.

Place: Bhopal
Date: 09.11.2020
UDIN: 20400340AAAADJ7258



For, Anup Shrivastava & Associates
Chartered Accountants
FRN No. 006455C


CA Sudeep Moitra
(Partner)
M. No. 400340